Krystal Biotech

$44.49
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.27 (+0.61%) As of 10:15 AM EST today

Why Robinhood?

You can buy or sell KRYS and other stocks, options, and ETFs commission-free!

About KRYS

Krystal Biotech, Inc. Common Stock, also called Krystal Biotech, is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA. The listed name for KRYS is Krystal Biotech, Inc. Common Stock.

CEO
Krish S. Krishnan
Employees
51
Headquarters
Pittsburgh, Pennsylvania
Founded
2016
Market Cap
886.64M
Price-Earnings Ratio
Dividend Yield
Average Volume
203.76K
High Today
$44.99
Low Today
$44.00
Open Price
$44.86
Volume
20.89K
52 Week High
$66.85
52 Week Low
$33.08

Collections

KRYS Earnings

-$0.49
-$0.33
-$0.16
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 9, After Hours

You May Also Like